“…Few other studies have evaluated the impact of BMI on various aspects of natalizumab therapy. The well-known wearing-off effect, particularly evident in the use of an EID, is influenced by BMI [ 29 , 30 ]. Other authors have hypothesized that a lower alpha integrin saturation in subjects with higher BMI could underlie the reduction in the efficacy of therapy [ 5 ].…”